Bioequivalency Study of Divalproex Sodium DR Tablets, 500 mg of Dr.Reddy's Under Fasting Conditions

Inclusion Criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: * Subjects who will provide written informed consent. * Subjects must be healthy, adult, human beings within 18-45 years of age (both inclusive)weighing at least 50 kg. * Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in Kg/height in m2 * Subjects must be of normal health as determined by medical history and physical examination performed within 21 days prior to the commencement of the study. * Subjects whose screening laboratory values are within normal limits or considered by the physician/investigator to be of no clinical significance. * Availability of the subject for the entire study period and willingness to adhere to the protocol requirements as evidenced by written informed consent. Exclusion Criteria: The subjects will be excluded based on the following criteria during screening and during the study * Subjects incapable of understanding the informed consent. * Subjects who have: * Systolic blood pressure less than 90 mm of Hg and more than 140 mm of Hg * Diastolic blood pressure less than 60 mm of Hg and more than 94 mm of Hg. Minor deviations (2-4 mm of Hg) at check-in may be acceptable at the discretion of the physician/investigator. * Pulse rate below 50/min and above 100/min. * History of hypersensitivity or idiosyncratic reaction to Divalproex sodium or any other related drugs. * Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function. * Consumption of grapefruit for the past ten days prior to the dosing day until the completion of the study. * Regular smoker who has a habit of smoking more than nine cigarettes per day and has difficulty in abstaining from smoking from 48 hours before dosing and during sampling period * Subjects who have taken over the counter or prescribed medications and enzyme modifying or any systemic medication for during the last 7 and 30 days respectively before dosing. * Subjects who have participated in any other clinical investigation using experimental drug/donated blood in past 90 days before the date of start of study. * Subjects with clinically significant abnormalities (such as Laboratory Findings, ECG, X-Ray,Drugs of abuse, Alcohol etc.,) and/or with significant diseases (such as HIV, HCV, Syphilis,Hepatitis B etc.,). * Female subjects who are pregnant or who are able (women with child bearing potential) to become pregnant during the study.